Eli Lilly has unveiled plans to construct a $5 billion manufacturing facility in Richmond, Virginia, which will produce the pharma’s bioconjugate and antibody therapies.

Lilly expects to create 2,450 jobs in the region, according to a statement from the company on Tuesday. Of these new roles, 650 will be “high-paying jobs” for skilled engineers, scientists, lab technicians and operations personnel, while the other 1,800 will be involved in the construction of the facility. The company expects to complete this project “within the next five years.”

At the new manufacturing plant, Lilly plans to concentrate operations on producing its monoclonal antibody and antibody-drug conjugate therapies, with a particular focus on cancer and immune-mediated indications. The new Virginia site will also incorporate “advanced technologies” such as automated systems and artificial intelligence, enabling what Lilly calls “right-first-time execution” for its products.